Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis

NCT06534814 · tracked via the Priya Life Science China tracker

Sponsor

Hebei Medical University

Phase

Observational

Started

2024-07-01

Last updated

2024-08-02

Condition(s) studied

The Primary Focus of This Study is on Gastric Cancer

Investigational drug(s) / intervention(s)

AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)

AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM): The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.

Study summary

The clinical trial titled "Development and Application of an Artificial Intelligence-Driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis" aims to enhance the detection and treatment of gastric cancer through the utilization of cutting-edge artificial intelligence (AI) technology. This study will develop an AI-driven model designed to accurately identify lymph node metastasis in patients with gastric cancer, which is crucial for staging the disease and planning effective treatment strategies.

The trial will involve a multidisciplinary team of oncologists, radiologists, data scientists, and AI experts who will collaborate to create a robust and precise identification system. Participants will undergo standard diagnostic procedures, and the AI model will analyze imaging and pathological data to predict lymph node involvement.

By comparing the AI model's predictions with traditional diagnostic methods, the study seeks to validate the model's accuracy and efficiency. This approach is expected to improve early detection rates, reduce diagnostic errors, and ultimately lead to better clinical outcomes for patients with gastric cancer. The successful implementation of this AI-driven model could revolutionize the current standards of care and serve as a blueprint for integrating AI technologies in other cancer diagnoses and treatments.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Diagnosis of Gastric Cancer: Confirmed diagnosis of gastric cancer, either newly diagnosed or recurrent. 2. Lymph Node Involvement: Suspected or confirmed involvement of lymph nodes, as indicated by imaging studies or pathology reports. 3. Age: Patients aged 18 years or older. 4. Performance Status: An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, indicating a functional status that allows participation in the study. 5. Informed Consent: Ability to provide written informed consent to participate in the study. Exclusion Criteria: 1. Pregnancy or Lactation: Pregnant or lactating women, due to potential risks to the fetus or infant. 2. Severe Comorbid Conditions: Presence of severe comorbid medical conditions that could interfere with the study or pose additional risks. 3. Previous AI-Driven Diagnostic Intervention: Prior use of any AI-driven diagnostic models specifically for gastric cancer lymph node metastasis. 4. Inability to Comply: Inability or unwillingness to comply with study procedures, including follow-up visits and data collection. 5. Mental or Cognitive Impairment: Conditions that impair the ability to provide informed consent or participate effectively in the study.

Primary outcome measure(s)

Identification of metastatic lymph nodes — 2025-12-31
A prediction model based on artificial intelligence technology was constructed to accurately identify metastatic perigastric lymph nodes before surgery.

Trial sites (1)

Facility	City	Region	Status
Department of General Surgery	Shijiazhuang	Hebei	Recruiting

More Hebei Medical University trials in China

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10 Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06534814 on ClinicalTrials.gov ↗ ← All trials in China